Healthcare provider profile · identity verified

Faiz Khalil Askar, M.D.

Internal Medicine · STERLING HEIGHTS, MI · NPI 1881860823

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	944	272
Amlodipine Besylate	Amlodipine Besylate	550	158
Losartan Potassium	Losartan Potassium	477	133
Metformin Hcl	Metformin Hcl	441	128
Metoprolol Succinate	Metoprolol Succinate	371	104
Levothyroxine Sodium	Levothyroxine Sodium	328	93
Lisinopril	Lisinopril	280	78
Omeprazole	Omeprazole	196	70
Famotidine	Famotidine	181	52
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	177	51
Tamsulosin Hcl	Tamsulosin Hcl	155	47
Eliquis	Apixaban	151	38
Rosuvastatin Calcium	Rosuvastatin Calcium	145	42
Potassium Chloride	Potassium Chloride	138	50
Jardiance	Empagliflozin	135	42
Atenolol	Atenolol	130	35
Allopurinol	Allopurinol	123	34
Furosemide	Furosemide	123	44
Simvastatin	Simvastatin	117	30
Spironolactone	Spironolactone	110	36
Metoprolol Tartrate	Metoprolol Tartrate	106	31
Gabapentin	Gabapentin	97	35
Fluticasone Propionate	Fluticasone Propionate	89	42
Carvedilol	Carvedilol	84	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	81	30
Ezetimibe	Ezetimibe	75	26
Alendronate Sodium	Alendronate Sodium	72	24
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	72	15
Finasteride	Finasteride	70	20
Trulicity	Dulaglutide	70	16
Pantoprazole Sodium	Pantoprazole Sodium	69	24
Benazepril Hcl	Benazepril Hcl	68	15
Albuterol Sulfate Hfa	Albuterol Sulfate	67	22
Chlorthalidone	Chlorthalidone	67	23
Donepezil Hcl	Donepezil Hcl	66	20
Clopidogrel	Clopidogrel Bisulfate	65	20
Memantine Hcl	Memantine Hcl	63	18
Hydrochlorothiazide	Hydrochlorothiazide	62	21
Tiotropium Bromide	Tiotropium Bromide	57	15
Escitalopram Oxalate	Escitalopram Oxalate	53	15
Warfarin Sodium	Warfarin Sodium	53	13
Pravastatin Sodium	Pravastatin Sodium	52	16
Ozempic	Semaglutide	50	suppressed
Nifedipine Er	Nifedipine	49	16
Sertraline Hcl	Sertraline Hcl	47	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	14
Folic Acid	Folic Acid	42	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	suppressed
Ipratropium Bromide	Ipratropium Bromide	37	13
Ventolin Hfa	Albuterol Sulfate	37	12
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	33	33
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	suppressed
Xarelto	Rivaroxaban	33	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	30	11
Amiodarone Hcl	Amiodarone Hcl	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	11
Trazodone Hcl	Trazodone Hcl	27	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	27	11
Colchicine	Colchicine	26	suppressed
Glimepiride	Glimepiride	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Klor-Con M10	Potassium Chloride	25	suppressed
Montelukast Sodium	Montelukast Sodium	25	suppressed
Terazosin Hcl	Terazosin Hcl	25	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Novolog Flexpen	Insulin Aspart	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Metformin Hcl Er	Metformin Hcl	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Prednisone	Prednisone	21	17
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Alprazolam	Alprazolam	20	suppressed
Felodipine Er	Felodipine	20	suppressed
Klor-Con M20	Potassium Chloride	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	19	suppressed
Lansoprazole	Lansoprazole	19	suppressed
Nystatin	Nystatin	19	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	19	suppressed
Temazepam	Temazepam	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Hydrocortisone	Hydrocortisone	17	suppressed
Torsemide	Torsemide	17	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Linzess	Linaclotide	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	12
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Repatha Syringe	Evolocumab	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	11
Sildenafil Citrate	Sildenafil Citrate	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Diazepam	Diazepam	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error